Kinnate Biopharma Stock Fair Value Calculation – Kinnate Biopharma Receives FDA Fast Track Designation for KIN-3248 to Treat Bile Duct Cancer.

Trending News 🌧️

Kinnate Biopharma Stock Fair Value Calculation – Kinnate Biopharma ($NASDAQ:KNTE), a pharmaceutical company dedicated to discovering and developing novel cancer treatments, announced on Tuesday that the U.S. Food and Drug Administration (FDA) had granted them fast track designation for KIN-3248, an inhibitor for treating bile duct cancer. This marks a major milestone for Kinnate, as it is the first product from their portfolio to receive such designation. KIN-3248 is an oral small molecule designed to inhibit the c-MET pathway for the treatment of bile duct cancer. The FDA’s fast track designation grants the drug expedited review and potential accelerated approval.

This expedited review timeframe could potentially allow for a quicker entry of KIN-3248 into the market, thus benefiting patients in need of a better treatment option. Kinnate Biopharma is a publicly traded biopharmaceutical company headquartered in San Francisco. As the company continues to develop their pipeline of therapies, they hope to bring further hope and relief to these patients and their families.

Price History

The FDA’s Fast Track Designation is intended to expedite the development and review of drugs that are intended to treat serious conditions and fill an unmet medical need. The news was received with mixed media sentiment, as most of the reports were negative. On Tuesday, the KINNATE BIOPHARMA stock opened at $6.6 and closed at $6.6. This reflects the market’s general sentiment regarding the news and that investors were not so optimistic about the drug’s chances of success. KIN-3248 was granted Fast Track Designation based on its potential to address a serious unmet need for patients with bile duct cancer, which is an aggressive malignancy with a very poor prognosis.

KIN-3248 has shown promise in animal studies, but more clinical trials are needed to evaluate its safety and efficacy in humans. The company is committed to continuing their research and development efforts to find a better solution to this deadly disease. They will also continue to seek out opportunities to collaborate with other organizations in order to create an effective treatment plan for patients around the world. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Kinnate Biopharma. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Kinnate Biopharma. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Kinnate Biopharma. More…

Key Ratios Snapshot

Some of the financial key ratios for Kinnate Biopharma are shown below. More…

Analysis – Kinnate Biopharma Stock Fair Value Calculation

GoodWhale’s analysis of KINNATE BIOPHARMA’s fundamentals suggests that the fair value of the stock is around $13.7. This fair value has been calculated using GoodWhale’s proprietary Valuation Line, which takes into account factors such as the company’s financial performance, industry dynamics and risk profile. Currently, KINNATE BIOPHARMA shares are trading at $6.6, which means that the stock is undervalued by 51.7%. This represents an opportunity for potential investors to buy the stock at a discounted price and potentially benefit from capital appreciation as the stock moves closer to its fair value. KINNATE BIOPHARMA’s commitment to innovation and high-quality products, coupled with their strong management team and sound financial performance, make it an attractive investment opportunity. Investors should consider the stock’s current undervaluation and potential for growth before making a decision about investing in KINNATE BIOPHARMA. More…

Peers

The company’s lead product candidate, IPI-549, is an orally-available, small molecule inhibitor of PI3Kγ. The company is also developing IPI-145, an inhibitor of Bruton’s tyrosine kinase (BTK), and IPI-180, an inhibitor of Janus kinases (JAKs). The company’s competitors include Pliant Therapeutics Inc, Epizyme Inc, Gossamer Bio Inc.

– Pliant Therapeutics Inc ($NASDAQ:PLRX)

Pliant Therapeutics, Inc. focuses on the development of therapies for the treatment of fibrotic diseases. The company’s lead product candidate is PLI-300, an orally-administered small molecule that inhibits the production of collagen by blocking the interaction between the alpha2beta1 integrin and collagen. PLI-300 is in Phase II clinical trials for the treatment of idiopathic pulmonary fibrosis and scleroderma. The company was founded in 2015 and is headquartered in San Francisco, California.

– Epizyme Inc ($NASDAQ:GOSS)

Gossamer Bio Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. The company’s market cap is $990.28 million and its ROE is -1952.91%. Gossamer Bio’s lead product candidate, GB226, is a Phase 2b-ready monoclonal antibody that is being developed for the treatment of moderate-to-severe atopic dermatitis, a chronic inflammatory skin condition.

Summary

Kinnate Biopharma is a biopharmaceutical company focused on developing innovative treatments for bile duct cancer. The company recently received FDA Fast Track Designation for its drug, KIN-3248, which has been shown to be effective in treating this rare and aggressive form of cancer. For potential investors, the news is encouraging, as it signals the potential for faster development and a faster route to market. In addition to this, Kinnate’s strong research and development capabilities and its experienced leadership team provide the promise of future success.

The company’s pipeline of drugs and its ability to continually develop new and improved treatments also adds to its appeal. Thus, investors should continue to monitor Kinnate Biopharma for further updates on its progress.